Tag Archive for: opthalmology

Breye Therapeutics raises €67.5 million in over-subscribed Series A financing

/in

Co-led by new investor Mission BioCapital and existing investor Novo Holdings, with additional investment from existing syndicate member Sound Bioventures, and new investors the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, and Pappas Capital Company will now advance danegaptide, a pioneering, first-in-class oral treatment for Non-Proliferative Diabetic Retinopathy (NPDR), into a […]

Read more

Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine

/in

Oral treatment danegaptide represents “a potential paradigm shift” toward earlier, non-invasive treatment of Non-Proliferative Diabetic Retinopathy (NPDR), say authors Study “provides compelling evidence” that danegaptide robustly protects inner blood-retina barrier (iBRB), while also dampening VEGF-associated activity This “dual approach”, and its ability to be used earlier, “may translate into improved outcomes” Breye is now planning […]

Read more

ReBio Pharma appoints leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer

/in

· Brings nearly three decades of clinical, translational and biotechnology experience, strengthening ReBio’s leadership team as it prepares to advance RBP-01 into the clinic · RBP-01 targets primary uveal melanoma, the most common primary eye cancer in adults and an indication with no approved therapies Turku, Finland and Geneva, Switzerland, 22 July2026 – ReBioPharma (“ReBio” […]

Read more

Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium

/in

Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR) with associated macular edema Oral treatment was well tolerated, showed signs of clinical effect and retinal imaging data consistent with reductions in vascular leakage, one of the core […]

Read more

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

/in

Investigating potential for an oral treatment in diabetic retinopathy First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, […]

Read more
© Optimum Strategic Communications.